By: Carol Fabian, MD
Date. 12/07/2023
In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will discuss critical aspects of breast cancer risk assessment and prevention. She will address the utility of polygenic risk scores, explaining how they complement imaging and influence decisions regarding risk reduction therapy.
Dr. Fabian will provide information on hormone replacement and alternatives for women at moderate to high risk of developing breast cancer. She will discuss safe alternatives considered in this context, focusing on choices aligned with patient safety and well-being.
The conversation will touch upon the presentation by Dr. Joanne Kotsopoulos, focusing on hormone replacement following premenopausal oophorectomy in BRCA1/2 mutation carriers. Dr. Fabian will offer insights into key considerations and recommendations arising from this presentation, providing information on managing hormonal aspects for individuals with a genetic predisposition to breast cancer.
Dr. Fabian’s expertise will extend to the significance of addressing menopausal symptoms as quality-of-life issues for high-risk women and breast cancer survivors. She will provide insights into the management of vasomotor symptoms during menopause transition, preventive endocrine therapy, or cancer treatment, emphasizing the impact on overall well-being.
Furthermore, Dr. Fabian will share her knowledge on the combination of bazedoxifene and conjugated estrogen as a hormonal treatment for vasomotor symptoms. She will discuss safety considerations and potential benefits, offering a comprehensive perspective, particularly in the context of ongoing trials examining its role in breast cancer risk reduction. Through this interview, Dr. Carol Fabian, MD, aims to provide information contributing to the understanding and advancement of breast cancer prevention strategies.